Becton, Dickinson shares rise as fresh Buy initiation adds to improving post-spin outlook

Becton, Dickinson and Company (BDX) is up 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is a new Buy initiation from UBS, which framed BD as a cleaner and potentially steadier story after the Waters transaction removed the Life Sciences business. The move may also be getting support from BD’s earlier profit guidance increase, aggressive share repurchases, and investor positioning ahead of its August 6 fiscal third-quarter earnings call.

Details:

UBS initiated coverage with a Buy rating and a $190 price target, arguing the stock’s valuation had compressed and that several recent growth headwinds should ease over time.

That analyst view highlighted the post-Waters portfolio as simpler and more focused, with expectations for better medium-term growth and a more shareholder-oriented capital allocation approach.

BD’s most recent quarterly update showed revenue growth, a higher full-year adjusted EPS outlook, and a reaffirmed revenue growth forecast, which helped reinforce a recovery narrative.

The company also disclosed a $2.0 billion accelerated share repurchase program and noted its next earnings conference call is scheduled for August 6, which can draw added attention to the stock.

Sources:

Becton, Dickinson and Company, Investing.com, StreetInsider

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BDX Insider Trading Activity

$BDX insiders have traded $BDX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $BDX stock by insiders over the last 6 months:

THOMAS E JR POLEN (Chairman, CEO and President) sold 2,764 shares for an estimated $404,511
MICHAEL DAVID GARRISON (EVP & Pres Med.Essntl&BioPharm) has made 0 purchases and 2 sales selling 2,200 shares for an estimated $326,854.
BERTRAM L SCOTT sold 953 shares for an estimated $174,027
MICHAEL FELD (EVP, Chief Revenue Officer) has made 0 purchases and 6 sales selling 449 shares for an estimated $70,939.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BDX Hedge Fund Activity

We have seen 605 institutional investors add shares of $BDX stock to their portfolio, and 730 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 4,140,223 shares (-99.6%) from their portfolio in Q1 2026, for an estimated $644,384,307
BLACKROCK, INC. removed 1,495,294 shares (-5.4%) from their portfolio in Q1 2026, for an estimated $232,727,558
ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 1,433,244 shares (-86.5%) from their portfolio in Q1 2026, for an estimated $223,070,096
WELLINGTON MANAGEMENT GROUP LLP added 1,316,200 shares (+24.8%) to their portfolio in Q1 2026, for an estimated $204,853,367
HOLOCENE ADVISORS, LP removed 1,088,801 shares (-93.4%) from their portfolio in Q1 2026, for an estimated $169,460,987
MANUFACTURERS LIFE INSURANCE COMPANY, THE removed 1,013,192 shares (-42.5%) from their portfolio in Q1 2026, for an estimated $157,693,202
FINDLAY PARK PARTNERS LLP added 983,500 shares (+inf%) to their portfolio in Q1 2026, for an estimated $153,071,940

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BDX Government Contracts

We have seen $123,329,416 of award payments to $BDX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PHARMACY INPATIENT AUTOMATION SUPPORT - ENTERPRISE MAINTENANCE AND SUPPORT SERVICES: $13,724,256
INFUSION PUMPS AND SERVICES: $5,519,658
INFUSION PUMPS MULTIPLE-AWARD IDIQ VISN 10 ORDER: $5,252,124
INFUSION PUMPS: $5,057,297
FLEET REPLACEMENT INFUSION PUMPS: $3,272,308

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$BDX Congressional Stock Trading

Members of Congress have traded $BDX stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BDX stock by members of Congress over the last 6 months:

REPRESENTATIVE THOMAS H. KEAN, JR. sold up to $15,000 on 05/21.
SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
REPRESENTATIVE KEVIN HERN sold up to $50,000 on 03/17.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BDX Price Targets

Multiple analysts have issued price targets for $BDX recently. We have seen 11 analysts offer price targets for $BDX in the last 6 months, with a median target of $175.0.

Here are some recent targets:

Vijay Kumar from Evercore ISI Group set a target price of $180.0 on 07/06/2026
Matt Miksic from Barclays set a target price of $204.0 on 05/11/2026
Lawrence Biegelsen from Wells Fargo set a target price of $161.0 on 05/08/2026
Joshua Jennings from TD Cowen set a target price of $163.0 on 05/04/2026
Jason Bednar from Piper Sandler set a target price of $159.0 on 04/17/2026
David Roman from Goldman Sachs set a target price of $167.0 on 04/10/2026
David Toung from Argus Research set a target price of $180.0 on 03/23/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.